(HLAL) Wahed FTSE USA Shariah - Overview
Etf: Technology, Healthcare, Consumer, Financials, Communication
Dividends
| Dividend Yield | 0.57% |
| Yield on Cost 5y | 0.97% |
| Yield CAGR 5y | -0.60% |
| Payout Consistency | 95.7% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 15.1% |
| Relative Tail Risk | 4.32% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.76 |
| Alpha | 2.88 |
| Character TTM | |
|---|---|
| Beta | 0.994 |
| Beta Downside | 0.987 |
| Drawdowns 3y | |
|---|---|
| Max DD | 21.67% |
| CAGR/Max DD | 0.90 |
Description: HLAL Wahed FTSE USA Shariah December 26, 2025
The Wahed FTSE USA Shariah ETF (NASDAQ: HLAL) tracks an index of large- and mid-cap U.S. equities that satisfy Shariah-compliance screens applied by qualified scholars. In practice, the fund aims to allocate at least 80 % of its net assets to the index constituents, and it is classified as a non-diversified, large-blend ETF.
Based on the most recent prospectus (as of Q3 2024), HLAL carries an expense ratio of roughly 0.48 % and holds about $210 million in assets under management, with top sector exposures to technology, consumer discretionary and health care-sectors that typically meet the interest-free and ethical criteria of Islamic finance. The fund’s performance is closely tied to macro-drivers such as U.S. GDP growth and Federal Reserve policy, because higher rates can compress valuations in interest-sensitive sectors that are often under-weighted in Shariah screens.
If you want a data-rich, side-by-side comparison of HLAL’s risk-adjusted returns and sector tilts, a quick look at ValueRay’s analytics could be a useful next step.
What is the price of HLAL shares?
Over the past week, the price has changed by +0.03%, over one month by +0.97%, over three months by +4.61% and over the past year by +18.76%.
Is HLAL a buy, sell or hold?
What are the forecasts/targets for the HLAL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 74.6 | 17.9% |
HLAL Fundamental Data Overview February 02, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 742.9m USD (742.9m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 742.9m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 742.9m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 9.58% (E(742.9m)/V(742.9m) * Re(9.58%) + (debt-free company))
Discount Rate = 9.58% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)